Market share of major cardiovascular internal drugs in China H1 2022
In the first half of 2022, Compound danshen dropping pills accounted for more than nine percent in the public healthcare market in China, ranked first among cardiovascular internal drugs. Meanwhile, Yiling Pharmaceutical's tongxinluo capsules remained an important cardiovascular internal drug.